Patten Group Inc. Sells 35,317 Shares of Astrazeneca Plc $AZN

Patten Group Inc. decreased its position in Astrazeneca Plc (NYSE:AZN) by 54.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,089 shares of the company’s stock after selling 35,317 shares during the period. Astrazeneca comprises approximately 1.0% of Patten Group Inc.’s holdings, making the stock its 15th largest holding. Patten Group Inc.’s holdings in Astrazeneca were worth $5,877,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its position in shares of Astrazeneca by 552.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after purchasing an additional 4,697,895 shares during the period. Pictet Asset Management Holding SA bought a new position in Astrazeneca in the first quarter worth $675,263,000. Bank of Montreal Can boosted its stake in Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after buying an additional 2,695,793 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in Astrazeneca during the first quarter worth $473,782,000. Finally, ABN AMRO Bank N.V. increased its holdings in Astrazeneca by 32,441.5% in the 1st quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock valued at $482,158,000 after buying an additional 2,437,657 shares during the period. Institutional investors own 20.35% of the company’s stock.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Stock Performance

NYSE AZN opened at $194.96 on Friday. The firm has a market cap of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. The company has a 50 day moving average of $183.91 and a 200-day moving average of $187.76. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, equities analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on AZN shares. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Bank of America reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.